Shire rejects $63 billion Takeda bid as Allergan drops pursuit

NEW YORK/LONDON (Reuters) - London-listed rare disease drug maker Shire Plc said on Thursday it had rejected a $63 billion cash-and-stock acquisition offer by Japan's Takeda Pharmaceutical Co , even as their talks continued, while Allergan Plc dropped its rival bid.